326 related articles for article (PubMed ID: 10698418)
21. The role of Tc-99m MDP and Ga-67 imaging in the clinical evaluation of malignant fibrous histiocytoma.
Lin WY; Kao CH; Hsu CY; Liao SQ; Wang SJ; Yeh SH
Clin Nucl Med; 1994 Nov; 19(11):996-1000. PubMed ID: 7842598
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of Tc-99m-MIBI performed during middle course of preoperative chemotherapy in patients with malignant bone and soft-tissue tumors.
Wakabayashi H; Taki J; Inaki A; Sumiya H; Zen Y; Tsuchiya H; Kinuya S
Clin Nucl Med; 2012 Jan; 37(1):1-8. PubMed ID: 22157020
[TBL] [Abstract][Full Text] [Related]
23. Value of thallium-201 scintigraphy in bone and soft tissue tumors.
Sato O; Kawai A; Ozaki T; Kunisada T; Danura T; Inoue H
J Orthop Sci; 1998; 3(6):297-303. PubMed ID: 9811980
[TBL] [Abstract][Full Text] [Related]
24. Correlation of 99mTc-sestamibi uptake with blood-pool and osseous phase 99mTc-MDP uptake in malignant bone and soft-tissue tumours.
Ozcan Z; Burak Z; Erinç R; Dirlik A; Başdemir G; Sabah D; Ozkiliç H
Nucl Med Commun; 2001 Jun; 22(6):679-83. PubMed ID: 11403180
[TBL] [Abstract][Full Text] [Related]
25. Differentiation of malignant and degenerative benign bone disease using Tc-99m MDP and Tc-99m citrate scintigraphy.
Sharma R; Mondal A; Bhatnagar A; Chakravarty KL; Mishra P; Chopra MK; Rawat HS; Kashyap R
Clin Nucl Med; 1998 Nov; 23(11):758-63. PubMed ID: 9814564
[TBL] [Abstract][Full Text] [Related]
26. The clinical value of bone and gallium scintigraphy for soft-tissue sarcomas of the extremities.
Kirchner PT; Simon MA
J Bone Joint Surg Am; 1984 Mar; 66(3):319-27. PubMed ID: 6230363
[TBL] [Abstract][Full Text] [Related]
27. [Clinical usefulness of thallium-201 chloride in the diagnosis of tumor (II)--An evaluation in bone, soft tissue and mediastinal tumors].
Tonami N; Itoh K; Yui N; Terui S; Torizuka K
Kaku Igaku; 1994 Jan; 31(1):63-74. PubMed ID: 8309112
[TBL] [Abstract][Full Text] [Related]
28. Predicting the outcome of distraction osteogenesis by 3-phase bone scintigraphy.
Kawano M; Taki J; Tsuchiya H; Tomita K; Tonami N
J Nucl Med; 2003 Mar; 44(3):369-74. PubMed ID: 12621002
[TBL] [Abstract][Full Text] [Related]
29. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities.
Moustafa H; Riad R; Omar W; Zaher A; Ebied E
Q J Nucl Med; 2003 Mar; 47(1):51-7. PubMed ID: 12714955
[TBL] [Abstract][Full Text] [Related]
30. The value of Tc-99m-tetrofosmin scintigraphy in the assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors.
Yapar Z; Kibar M; Yapar AF; Uguz A; Ozbarlas S; Gonlusen G
Ann Nucl Med; 2003 Sep; 17(6):443-9. PubMed ID: 14575377
[TBL] [Abstract][Full Text] [Related]
31. The role of nuclear medicine in primary bone and soft tissue tumors.
Abdel-Dayem HM
Semin Nucl Med; 1997 Oct; 27(4):355-63. PubMed ID: 9364645
[TBL] [Abstract][Full Text] [Related]
32. [Preliminary application of 99Tc(m)-MIBI scintigraphy for judgment of bone malignant and benign lesions].
Jia ZY; Deng HF
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 38(4):689-92. PubMed ID: 17718443
[TBL] [Abstract][Full Text] [Related]
33. Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: comparison with Tl-201 imaging.
Taki J; Higuchi T; Sumiya H; Tsuchiya H; Minato H; Tomita K; Tonami N
J Orthop Res; 2008 Mar; 26(3):411-8. PubMed ID: 17960652
[TBL] [Abstract][Full Text] [Related]
34. Soft-tissue tumors: diagnosis with Tc-99m (V) dimercaptosuccinic acid scintigraphy.
Kobayashi H; Sakahara H; Hosono M; Shirato M; Endo K; Kotoura Y; Yamamuro T; Konishi J
Radiology; 1994 Jan; 190(1):277-80. PubMed ID: 8259419
[TBL] [Abstract][Full Text] [Related]
35. Tl-201 and Tc-99m HMDP scintigraphic findings in extraskeletal osteosarcoma.
Kajihara M; Sugawara Y; Miki H; Mochizuki T; Kidani T; Sakayama K
Clin Nucl Med; 2005 May; 30(5):356-8. PubMed ID: 15827415
[TBL] [Abstract][Full Text] [Related]
36. [99mTc-HMDP accumulation in soft tissue tumor].
Momose M
Kaku Igaku; 2000 Nov; 37(6):639-43. PubMed ID: 11193449
[TBL] [Abstract][Full Text] [Related]
37. Midcourse thallium-201 scintigraphy to predict tumor response in bone and soft-tissue tumors.
Sumiya H; Taki J; Tsuchiya H; Nonomura A; Miyauchi T; Tonami N
J Nucl Med; 1998 Sep; 39(9):1600-4. PubMed ID: 9744351
[TBL] [Abstract][Full Text] [Related]
38. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
39. Differentiation of malignant and degenerative bone lesions using dexamethasone interventional 3- and 24-hour bone scintigraphy.
Bhatnagar A; Mondal A; Kashyap R; Sharma RK; Sharma R; Chakravarty SK; Bihari V; Sawroop K; Chopra MK; Soni NL
Eur J Nucl Med; 1994 Jul; 21(7):609-14. PubMed ID: 7957346
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of ultrasonography and TI-201/Tc-99m dual scintigraphy in differentiating between benign and malignant thyroid nodules.
Watanabe K; Igarashi T; Ashida H; Ogiwara S; Ohta T; Uchiyama M; Ojiri H
Endocrine; 2019 Feb; 63(2):301-309. PubMed ID: 30276595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
